Tetrous® Reaches Milestone of 5,500 EnFix® Implants in Orthopedic Markets
Tetrous® Reaches Milestone of 5,500 EnFix® Implants in Orthopedic Markets
Tetrous, Inc., an emerging leader in the field of orthopedic sports medicine, has hit a significant milestone with over 5,500 EnFix® demineralized bone fiber (DBF) implants successfully placed since their commercial launch. This remarkable achievement highlights not just the potential of their product, but also increasing confidence among surgeons regarding its effectiveness in addressing a persistent challenge in orthopedic surgery – the restoration of the bone-to-tendon interface, known as enthesis.
Unveiling the EnFix Portfolio
The EnFix portfolio includes several variants such as EnFix RC®, EnFix TAC-O®, EnFix TAC-T®, and EnFix ACL®, all meticulously designed for placement within the bone at the soft-tissue attachment site. These implants aim to support the body’s natural healing response particularly in critical areas where bone meets tendon.
The journey of EnFix began with a controlled commercial launch in July 2023 in partnership with just seven surgeons, targeting both Australia and the United States. Over time, this initiative has witnessed impressive growth in its adoption, clinical applications, and geographical reach, marking Tetrous's dedication to improving patient outcomes in sports medicine.
Impressive Growth Metrics
Since its inception, EnFix has made remarkable strides:
- - The product has been utilized in applications involving shoulders, knees, hips, and ankles, with over 5,500 implants now documented.
- - Tetrous has expanded operations beyond the U.S. and Australia, reaching out to countries such as New Zealand and Puerto Rico.
- - The company has broadened its portfolio, enabling it to cater to a wider array of orthopedic soft tissue repair needs.
- - Noteworthy clinical data has emerged, underscoring the importance of DBF in promoting healing at the bone-tendon interface.
Bradley Patt, PhD, co-founder and CEO of Tetrous, expressed enthusiasm regarding the company’s progress: “Surpassing 5,500 implants reflects growing surgeon confidence in the importance of addressing the biology of bone-to-tendon healing.” The positive clinical data has positioned the DBF technology as a vital asset in enhancing surgical outcomes and might lead to significant improvements in patients’ recovery processes.
A Shift in the Paradigm
Experts like Jonathan Godin, MBA, MD, from The Steadman Clinic, have pointed out the revolutionary nature of EnFix, asserting, “It’s the first-in-class of augments in the actual healing between the bone and the tendon.” Unlike traditional augmentation methods that are typically positioned externally on the tendon, EnFix is strategically placed within the bone, specifically at the interface where healing is critical. This focused approach helps harness the body’s biological mechanisms effectively by exposing the DBF’s naturally occurring bone morphogenetic proteins (BMPs), guiding cellular responses to support the healing journey.
Dr. Bellard also noted, “Reaching 5,500 implants demonstrates that surgeons are increasingly looking beyond simple fixation and considering the biological aspects of healing at the enthesis.” This promising trend underscores the shift towards a more integrated and biology-focused approach in orthopedic practices.
The Future of Tetrous
Established in 2019, Tetrous, Inc. is committed to revolutionizing orthopedic sports medicine through advanced technologies for enthesis repair. The EnFix family of implants remains at the forefront of this mission, enhancing the natural healing response by facilitating biological reformation at the critical juncture of tendon and bone.
Given its robust intellectual property lineup and exclusive licenses for the technology, Tetrous is well-positioned to continue pushing boundaries in orthopedic recovery strategies. The company strives to deliver clinically validated outcomes that demystify healing potential, emphasizing reduced failure rates and expedited recovery times for patients returned to their daily activities.
Interested parties may find more information by visiting Tetrous, Inc. or engaging with their updates on LinkedIn. As the orthopedic field evolves, Tetrous remains dedicated to leading advancements that support both surgeons and patients in achieving optimal outcomes.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.